quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:07·32d
SECFiling
Oragenics Inc. logo

SEC Form EFFECT filed by Oragenics Inc.

OGEN· Oragenics Inc.
Health Care
Original source

Companies

  • OGEN
    Oragenics Inc.
    Health Care

Related

  • PR3d
    Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
  • SEC10d
    Oragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR10d
    Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
  • SEC23d
    Oragenics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits
  • PR29d
    Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
  • SEC35d
    Amendment: SEC Form S-3/A filed by Oragenics Inc.
  • PR37d
    ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
  • SEC38d
    SEC Form 10-K filed by Oragenics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022